medigraphic.com
ISSN 1029-3035 (Electronic)

2012, Number s1

<< Back Next >>

Mediciego 2012; 18 (s1)

Use of recombinant interferon alpha 2b and Ribavirin in chronic liver injury caused by C virus in patients not answering to monotherapy

Estrada GY, Camacho AJ, Lebroc PD

Language: Spanish
References: 31
Page:
PDF size: 63.84 Kb.


ABSTRACT

A descriptive observational study of cross-section, was conducted with the aim of describing the results and tolerability of combined therapy with recombinant interferon alfa 2b and ribavirin in the re-treatment of patients with injury caused by hepatitis C virus, 17 patients treated in the hepatology consultation,were selected from Gastroenterology Service of Provincial teaching Hospital "Dr. Antonio Luaces Iraola", that not respond to a first treatment with interferon as monotherapy; the data were obtained in the form of data collection. Patients with chronic hepatitis C were mostly young and male adults. The most affected population groups were patients with unprotected or sexual risk behaviour, patients with a history of stomatological care, blood transfusion receptors and medical personnel. A combined therapy was applied to them for 52 weeks, 58% of the studied patients were negative at the end of the treatment, 94% normalized Alanine aminotransferase, a histological improvement regarding the initial biopsy in the majority of cases was observed, the most common adverse reaction was the flu syndrome.


REFERENCES

  1. Liang TJ. Pathogenesis natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4): 296-305.

  2. Torres Puente M, Cuevas JM, Jiménez Hernández N, Bracho MA, García Robles I, Wrobel B, et al. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J Viral Hepat. 2008; 15(3):188-199.

  3. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 1999; 7:402-410.

  4. Patel K, Muir AJ, Mc Hutchison JG. Diagnosis and treatment of chronic hepatitis C infection. Br Med J. 2006; 332:1013-1017.

  5. Sheehy P, Mullan B, Moreau I, Kenny-Walsh E, Shanahan F, Scallan M, et al. In vitro replication models for the hepatitis c virus. J Viral Hepat. 2007; 14 (1): 2-10.

  6. Pietschmann TH. Regulation of hepatitis C virus replication by micro RNAs. Hepatology. 2009; 50:441-444.

  7. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 1994; 19: 1321-1324.

  8. Mindikoglu AL, Miller RR. Hepatitis C in the elderly: epidemiology, natural history, and treatment. Clin Gastroenterol Hepatol. 2009; 7(2):128-134.

  9. Cole A. Hepatitis C morbidity is set to double in next decade. Br Med J. 2007; 334:10.

  10. Agarwal K, Cross TJ, Gore CH. Chronic hepatitis C. Br Med J. 2007; 334: 54-55.

  11. Warley E, Desse J, Szyld E, Silva FN, Cetani S, Pereyra N. Occupational exposure to hepatitis C virus. Med (Buenos Aires). 2006; 66(2): 97-100.

  12. Vilar Gómez J. Influencia de factores epidemiológicos en la progresión de la fibrosis en la hepatitis crónica C. Rev Cubana Med. 2003; 42(5): 1-7.

  13. Bruguera M. Prevención de las hepatitis virales. Enferm Infecc Microbiol Clin. 2006; 24(10): 649-56.

  14. Nakashima K, Kashiwagi S, Hayashi J. Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am J Epidemiol. 1992; 136: 1132-1137.

  15. Gutiérrez P, Orduña A, Bratos MA. Prevalence of anti-hepatitis C virus antibodies in positive FTA-ABS non-drug abusing female prostitutes in Spain. Sex Trans Dis. 1992; 19: 39-40.

  16. Alter MJ, Hadler SC, Judson FN. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. J Am Med Assoc. 1990; 264: 2231- 2235.

  17. Carnicer Jáuregui F. Epidemiología de la hepatitis C. Rev Soc Valenciana Patol Digest. 2002; 21(3): 160-165.

  18. McHutchinson JG. Interferon Alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N England J Med. 1998; 339: 1485-1492.

  19. Thierry P. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998; 352: 1426-1432.

  20. Buti M. Tratamiento de la hepatitis crónica C. Factores relacionados con la respuesta. GH Cont. 2006; 1(2):1-4.

  21. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat. 2006; 13(5): 297-302.

  22. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat. 2006; 13(5): 297-302.

  23. Karpinska E, Wawrzynowic Z, Syczewska M, Jurczyk K, Moranska I, Urbanowicz W, et al. Efficacy of combination therapy with interferon alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity. Wiad Lek. 2005; 58(11-12): 616-621.

  24. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol. 2005; 42(Suppl 1): S22-36.

  25. Tsukada S, Parsons C, Rippe R. Mechanisms of liver fibrosis. Clin Chim Acta. 2006; 364: 33- 60.

  26. Kelleher T, Afdhal N. Assessment of fibrosis in clinical practice. In: Arroyo V, Forns X, Bataller R, Sánchez Fueyo A, Rodés J, eds. Update in treatment of liver disease. Barcelona: Ars Méd. 2005; 463-74.

  27. Samaniego García J. Manejo de los efectos adversos del tratamiento antiviral en la hepatitis C crónica. Gastroenterol Hepatol. 2006; 29(Supl 1):31-6.

  28. Fried M. Side effects of therapy for hepatitis C and their management. Hepatology. 2002; 36:237-44.

  29. Pockros P, Siffman M, Schiff E. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004; 40:1450-8.

  30. Pojoga C, Dumitrascu DL, Pascu O, Grigorescu M. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The romanian experience. J Gastrointest Liver Dis. 2006; 15(1): 31-5.

  31. Lebray P, Naoals B, Vallet-Pichard D. The impact of haematopoietic growth on the management and efficacy of antiviral treatment in patients with hepatitis C virus. Antivir Ther. 2005; 10:769-76.




2020     |     www.medigraphic.com